All In Biotech

Drug Trial Radar · NCT02601235

Efficacy and Safety of Pediatric Drugs in Nasal Congestion

Clinical Evaluation of Safety and Efficacy of Pediatric Naridrin in Comparison to Afrin on the Improval of Nasal Congestion.

Last checked: Nov 19, 2026Latest source record: Oct 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 292 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

292

Actual

Start

Jan 16, 2018

Primary completion

Aug 3, 2018

Study completion Apr 3, 2019

Sponsor

Lead sponsor
EMSIndustry
Sponsor type
Industry
First posted
Nov 10, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 10 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of the Naridrin in improving nasal congestion.

Conditions

  • Nasal Congestion

Interventions

  • NaridrinDrug

    Naridrin® : 2 drops in each nostril once daily as prescription

  • AfrinDrug

    2 pumps in each nostril every 12 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relief of Nasal CongestionTime frame: 2 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Faculdade de Medicina do ABC

    Santo André, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.